StockTipsArenaBeta

BUY Piramal Pharma Limited — Mahesh Ojha, Kantilal Chhaganlal Securities

BUYPiramal Pharma Limited
Piramal Pharma share price target & all analyst calls

byMahesh Ojha, Kantilal Chhaganlal SecuritiesHorizon: 1 year28 Oct 2026via NDTV Profit

Entry₹232.57Inferred
Target₹280
Total upside +20.39%
Stop lossNot given
CMP₹232.87h ago
Active+0.10%+20.27%upside left 12 mo left
Follow Mahesh Ojha for new callsGet alertsWatch PPLPHARMA for new buy/sell callsGet alertsSee 5 other Long-term calls on PPLPHARMASee 200 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 28 Oct, 11:42 pm IST
21 supporting7 neutral4 opposing
Supports the BUY call (21)

Telecom could become one of Nifty’s biggest sectors after financials, says ICICI Securities

NewsCnbc-Tv18·28 Oct · today

(opens in new tab)

Piramal Pharma shares surge 14% as Q2 profitability improves, FY27 outlook raised

NewsCnbc-Tv18·28 Oct · today

(opens in new tab)

ICICI Securities sees telecom among Nifty's biggest sectors as tariff hike nears

NewsCnbc-Tv18·28 Oct · today

(opens in new tab)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·28 Oct · today

Piramal Pharma Q2 Results: Firm swings to profit as revenue jumps 28%, led by CDMO growth

NewsCnbc-Tv18·27 Oct · yesterday

(opens in new tab)
Neutral / worth noting (7)

Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·27 Oct · yesterday

(opens in new tab)

These four pharma stocks will be reacting to important news updates today

NewsCnbc-Tv18·5 Oct · 3w ago

(opens in new tab)
Weighs against the BUY call (4)

Piramal Pharma received a GST order demanding Rs 4.06 crore in input tax credit plus an equivalent penalty of Rs 4.06 crore. The company plans to appeal the order and does not expect a material impact

NSE · Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company·29 Sept · 4w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Piramal Pharma

All analyst calls on Piramal Pharma

More from Mahesh Ojha, Kantilal Chhaganlal Securities

Every call and its outcome